Menopause and the "Sugar-Coated" Hallmark of Aging (New Study)

#1

The Buck Institute for Research on Aging has launched the GRACE (Glycation Reduction and Aging: a Clinical Evaluation) trial to investigate whether a specific five-compound supplement can reverse metabolic decline in postmenopausal women. The study targets glycation stress, a biological process where sugars bond to proteins and fats, creating Advanced Glycation End-products (AGEs). These “sugar-coated” molecules drive inflammation and metabolic dysfunction, and their accumulation accelerates significantly after menopause due to the decline in estrogen.

The intervention utilizes GLYLO, a formulation containing alpha-lipoic acid, nicotinamide, pyridoxine, benfotiamine, and piperine. Preclinical data in mice indicates that this combination reduces the burden of methylglyoxal (MGO)—a highly reactive precursor to AGEs—while improving insulin sensitivity and extending lifespan. The GRACE trial represents the first human randomized controlled trial (RCT) specifically designed to translate these findings to a high-risk demographic: women aged 45–65 with elevated central adiposity and pre-diabetic glycemic markers.

Participants will undergo a 24-week double-blind regimen. Researchers will measure primary outcomes via serum levels of glycation stress markers such as CEL, MG-H1, and CML using advanced mass spectrometry. Beyond blood chemistry, the trial utilizes cutting-edge geroscience tools, including a deep-learning “retinal aging clock” (eyeAge) and skin autofluorescence to assess biological age gaps. By focusing on underlying aging biology rather than just individual symptoms like hot flashes, the GRACE study aims to determine if targeting glycation can preserve metabolic and functional health during the postmenopausal transition.

Actionable Insights

The primary message for health optimization is the identification of glycation stress as a modifiable driver of biological aging. While the trial results are pending, the study highlights five GRAS (Generally Recognized As Safe) compounds that potentially act synergistically to enhance endogenous detoxification of methylglyoxal (MGO):

  • Benfotiamine (100 mg): A fat-soluble derivative of Vitamin B1 that inhibits AGE formation.

  • Nicotinamide (200 mg): A form of Vitamin B3 that supports NAD+ pathways and cellular defenses.

  • Pyridoxine (50 mg): Vitamin B6, known to inhibit glycation.

  • Alpha-lipoic acid (150 mg): A potent antioxidant that improves glycemic control.

  • Piperine (10 mg): Included to potentially enhance the bioavailability of other components.

Individuals at high metabolic risk—specifically those with HbA1c levels between 5.5% and 6.4% or increased waist circumference—should prioritize strategies that lower MGO levels. This includes monitoring dietary intake of exogenous AGEs (found in highly processed and high-heat-cooked foods) and considering supplements that support glyoxalase-related detoxification pathways.

Study Context

Links:

Related Reading:

1 Like